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ABSTRACT
Objective: Lung volume reduction surgery for
emphysema leads to improved survival in appropriately
selected individuals, and it is therefore recommended
in national and international guidelines for this group
of patients. Despite this, fewer than 100 patients
undergo the procedure each year in the UK. Our
objective was to establish whether this reflects
concerns about morbidity and mortality or difficulties
in the referral pathway.
Design and setting: We conducted a survey of
members of the British Thoracic Society by email to
investigate this in the second half of 2013. The survey
included questions about access to investigations, the
indications for lung volume reduction surgery (LVRS),
whether a multidisciplinary meeting discussed
eligibility of patients for LVRS and what the morbidity
and mortality associated with the procedure was.
Results: There were 65 responses, 82% from
respiratory physicians. Roughly half of the respondents
were either unsure about the risks of death or
prolonged (>30 days) hospital stay involved or
significantly over-estimated them. In total, 70% did not
have a specific multidisciplinary team to discuss the
management of patients with advanced chronic
obstructive pulmonary disease (COPD). There was no
consensus as to which patients with COPD should
undergo a CT scan to evaluate them for possible
surgery.
Conclusions: Patients with COPD require a systematic
and multidisciplinary approach to assessment for LVRS
and these survey data suggest that work is needed to
deliver this evidence-based therapy in a consistent and
comprehensive way across the UK.
BACKGROUND
Chronic obstructive pulmonary disease
(COPD) is a major cause of disability and
mortality in the UK and is now the third
most frequent cause of death worldwide1 2 as
a consequence of the ongoing epidemic of
tobacco addiction.3 The pathological pro-
cesses involved, destruction of small airways
and lung parenchyma as well as narrowing of
larger airways, are poorly responsive to
medical therapies and many patients remain
severely disabled despite optimum medical
therapy.4 Only a handful of treatments
including smoking cessation, long-term
oxygen therapy in selected patients and lung
volume reduction surgery (LVRS) have been
shown to improve prognosis.5–8
LVRS was described as a palliative treatment
for emphysema by Brantigan and Muller in
1957.9 The aim of LVRS is to resect the most
emphysematous portion of the lung. This
allows healthier, less compliant areas to be
ventilated more effectively, reduces operating
lung volumes and thus improves chest wall
and respiratory muscle mechanics. In the US
National Emphysema Treatment Trial
(NETT),5 6 patients with an upper lobe pre-
dominant pattern of emphysema and a low
preoperative exercise capacity gained the
maximum beneﬁt and had increased survival,
which long-term economic analysis suggests is
achieved at an acceptable cost per
quality-adjusted life year.10 The NETT study
also identiﬁed a group of patients with an
excess risk of surgical mortality: those with
KEY MESSAGES
▸ The paper describes a survey sent to all
members of the British Thoracic Society to find
out about attitudes and knowledge around lung
volume reduction surgery, showing that there is
uncertainty and overestimation of the risks asso-
ciated with the procedure.
▸ The response rate was low, but that itself may
reflect a lack of engagement with lung volume
reduction surgery as a treatment for people with
emphysema.
▸ Although the low response rate impacts on the
precision of some of the estimates the respon-
ders are likely to have been better informed and
results from a larger group are unlikely to have
presented a ‘better’ picture.
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a forced expiratory volume 1 s (FEV1) <20% predicted
and either homogeneous disease or a carbon monoxide
transfer factor <20% predicted. The mortality rate for
patients excluding this high-risk group was 5.2% at
90 days. In the NETT trial, complications included major
respiratory or cardiac complication in 29.8% and 20% of
patients, respectively. At 1 month, 28.1% of patients were
still hospitalised or in a long-term care facility. However,
audit of current practice suggests that mortality and mor-
bidity are signiﬁcantly lower.11
Data from the UK Society of Cardiothoracic Surgery
(SCTS) register, http://www.scts.org/professionals/audit_
outcomes.aspx show that only 96 procedures in 2009–2010
and 90 in 2010–2011 were recorded. The likely pool of eli-
gible patients is signiﬁcantly larger than this12 and there is
therefore concern that patients who may beneﬁt are not
being considered for treatment. Some authors have sug-
gested that physicians are deterred from referral as LVRS
is perceived as too complicated with limited patient
beneﬁt and a substantial risk of complications.5 To
improve understanding of the obstacles limiting provision
of LVRS to suitable patients with COPD, we undertook a
survey of members of the British Thoracic Society (BTS).
METHODS
A survey including questions about clinicians’ attitudes
to and knowledge of LVRS was designed in collaboration
with the British Thoracic Society Professional and
Organisational Standards of Care Committee of the
BTS. The survey is available in the online supplementary
material. The survey was completed electronically and a
link to complete it sent out to 2498 BTS members in the
monthly e-newsletter on two occasions.
RESULTS
There were 65 respondents to the questionnaire with
replies from all UK nations and 13 different regions in
total. A total of 82% were consultant physicians and 11%
specialist trainees in respiratory medicine (table 1). The
remainder comprised two respiratory nurses, one thor-
acic surgeon, one physiotherapist and one clinical physi-
ologist. Twenty two (34%) identiﬁed themselves as the
COPD lead for their organisation.
Indications for LVRS, morbidity and mortality
In identifying which patients would derive the most
beneﬁt from LVRS, 60% of respondents correctly identi-
ﬁed those with heterogeneous emphysema and a low
exercise capacity. Estimates for a 30-day mortality were
0–5% in 52% of respondents, 21% overestimated this
and 27% did not know. A third of the respondents
thought that more than 10% of patients would be in
hospital 1 month postprocedure and 28% were unsure.
Process issues around LVRS
Roughly half of the respondents (52%) worked in a
teaching hospital and the remainder within district
general hospitals. A lung volume reduction service was
available in 27% of respondents’ hospitals and a further
41% had a centre within 20 miles. When asked about the
referral of patients for LVRS, 68% had referred patients
for LVRS in the past 12 months and 97% said that they
knew how to make a referral for LVRS. The number of
referrals by each respondent is listed in table 2. The
majority of respondents (70%) did not have a multidis-
ciplinary team (MDT) to discuss such cases within their
hospital, although 54% answered that an MDT was avail-
able in their local referral centre. Of those respondents
who worked in a referral centre, 65% had an MDT to
discuss LVRS cases. Bronchoscopic lung volume reduc-
tion was available in the hospital of 13% of respondents
with a further 21% planning to offer a service in the
future.
Access to investigations for the work-up for LVRS is
detailed in table 2. When asked whether a CT scan was
indicated for patients with COPD with an FEV1 <50%
predicted, 32% agreed or strongly agreed while 44% dis-
agreed or strongly disagreed.
In the free text section, 18 respondents left comments.
One surgeon felt that there were likely to be many more
patients who may beneﬁt but were not being recognised
as potential candidates. Two physicians commented that
there was a misconception regarding the beneﬁts and
risks of surgery. Another remarked that referral criteria,
particularly regarding exercise capacity, were not always
clear. One physician added that determining emphy-
sema heterogeneity was rarely performed at their centre.
Access to pulmonary rehabilitation was mentioned by
two respondents. Three physicians commented that they
were increasingly opting for bronchoscopic procedures,
while another felt that there was insufﬁcient evidence
for their use.
DISCUSSION
The main ﬁndings from the present survey are, ﬁrst, that
there are signiﬁcant information needs around the indi-
cations for LVRS and the accompanying risks of morbid-
ity and mortality. Second, there is a lack of systematic
structures to evaluate patients and, third, there is a lack
of consensus about the best approach for screening indi-
viduals to identify potential candidates for LVRS.
LVRS for selected patients is recommended in national
and international guidelines for the management of
COPD.13 14 This survey suggests that the majority of those
surveyed know how to refer patients for LVRS and had
done so within the last year. A signiﬁcant proportion of
respondents were clinical leads for COPD in their organ-
isation and the majority had referred a patient for poten-
tial LVRS in the last year, suggesting that the respondents
were likely to represent the more engaged clinicians in
this area. However, survey responses suggest that published
historical data from the late 1990s and early 21st century
inform many individuals’ assessment of risk. In current
surgical practice with largely unilateral, thoracoscopic
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Table 1 Summary of question results
Total Percentage
What is your role? (n=65)
Consultant physician 53 82
Consultant surgeon 1 2
Specialty trainee 7 11
Specialty trainee (other specialty) 0 0
Foundation trainee 0 0
Physiotherapist 1 2
Lung physiologist 1 2
Respiratory nurse 2 3
Where is your main place of work? (n=63)
Secondary care—DGH 30 48
Secondary care—teaching hospital 33 52
Are you the COPD lead for your organisation? (n=64)
Yes 22 34
No 42 66
I have referred a patient for consideration of LVRS within the past 12 months (n=63)
Yes 43 68
No 18 29
Not applicable 2 3
If ‘yes’, approximately how many patients have you referred for LVRS in the past 12 months? (n=45)
1–3 35 78
4–6 6 13
More than 6 3 7
Not known 1 2
I know how to refer patients for LVRS (n=63)
Yes 61 97
No 1 2
Not sure 1 2
Do you have a specific MDT meeting to discuss the management of patients with advanced COPD? (n=64)
Yes 18 28
No 45 70
Not known 0 0
Not applicable 1 2
Does the thoracic surgical service you use have an MDT to discuss potential LVRS patients? (n=63)
Yes 34 54
No 14 22
Not known 14 22
Not applicable 1 2
How far away is the nearest LVRS service? (estimate) (n=64)
On site 17 27
Less than 20 miles away 26 41
Between 20 and 40 miles away 8 12
Over 40 miles away 12 19
Not known 1 2
What do you estimate the 30 day mortality is following LVRS? (n=63) (%)
0–5 33 52
6–10 9 14
11–15 1 2
>15 3 5
Not known 17 27
What proportion of patients do you think would still be in hospital 30 days following LVRS? (n=65) (%)
0–4 10 16
5–9 17 27
10–15 14 22
>15 6 9
Not known 18 28
Which group of patients derive the most benefit from LVRS? (n=65)
Homogeneous emphysema, low exercise capacity 10 15
Continued
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approaches for LVRS, the morbidity and mortality are sig-
niﬁcantly lower than reported in the NETT trial5 with no
deaths within 90 days and only 6% of patients in hospital
at 30 days reported in one recent series.11
Most hospitals appear to have easy access to appropriate
investigations, but there was no consensus on when a CT
of the thorax is indicated. It has been proposed that a
routine assessment of the pattern of emphysema by CT
scan, as well as gas transfer measurement, should be con-
sidered in all patients with COPD with Medical Research
Council dyspnoea scores of 4 or 5 and an FEV1<50%,
unless there are obvious comorbidities precluding surgery,
with review by an MDT including chest physicians, sur-
geons and radiologists, as is already the case for the man-
agement of lung cancer.15 Clearly, this requires decisions
about the appropriate allocation of resources to ensure
best value. The cost per quality-adjusted life year of LVRS
in the NETT study in upper lobe predominant emphy-
sema was estimated to be $48 000 for low exercise capacity
and $40 000 for high exercise capacity patients at
10 years.10 The true cost in current practice is likely to be
considerably lower than this as the costs are driven by early
surgical morbidity and mortality, which are lower now.11 16
The response rate to the survey was low, which impacts
on the precision of the ﬁndings. We have no data as to the
reasons for non-response, and can therefore only specu-
late. However, as a self-selecting group, respondents may
be expected to have been more interested in LVRS, so it is
unlikely that responses from a larger sample would have
produced ‘better’ results. Clearly, people may have been
too busy to respond, but non-response itself may also rep-
resent a general lack of engagement with lung volume
reduction strategies in COPD. The overestimation of mor-
tality risk by half of the respondents and the overesti-
mation of hospital stay by 60% of the respondents may
contribute to this disengagement. A further consequence
of this is that low referral rates have made the development
of bronchoscopic approaches,17–20 intended to deliver
lung volume reduction either more safely or in different
emphysema phenotypes,21 22 more difﬁcult.
Lung volume reduction has a strong evidence base in
appropriately selected patients with COPD where, unlike
current pharmacotherapy, it can modify the natural
history of the disease.5 19 23 The survey conﬁrms that work
is needed to ensure that clinicians are aware of the risks
and beneﬁts associated with the technique in modern
Table 1 Continued
Total Percentage
Homogeneous emphysema, high exercise capacity 3 5
Heterogeneous emphysema, low exercise capacity 41 63
Heterogeneous emphysema, high exercise capacity 12 18
Not known 3 3
CT scanning may be indicated for haemoptysis, recurrent exacerbations or to investigate hypoxia, looking at pulmonary
arteries or for interstitial fibrosis. Excluding these specific indications, do you think a CT of the thorax is indicated routinely in
patients with an FEV1 <50% predicted? (n=65)
Strongly agree 4 6
Agree 17 26
Neither agree nor disagree 15 23
Disagree 25 38
Strongly disagree 4 6
Various bronchoscopic techniques which are intended for lung volume reduction are being developed—which option best
applies to your organisation? (n=63)
We currently offer bronchoscopic lung volume reduction 8 13
We intend to offer bronchoscopic lung volume reduction 13 21
We have no plans to offer bronchoscopic lung volume reduction 37 59
Not applicable 3 5
Not known 2 3
COPD, chronic obstructive pulmonary disease; DGH, district general hospital; LVRS, lung volume reduction surgery; MDT, multidisciplinary
team.
Table 2 Access to investigations for lung volume reduction surgery
Easy to access Hard to access Unavailable Not known
n Percentage n Percentage n Percentage n Percentage
Plethysmographic lung volumes 53 82 2 3 10 15 0 0
Gas transfer 65 100 0 0 0 0 0 0
Quantitative perfusion scanning 36 55 10 15 10 15 9 14
Walking tests 53 82 8 12 4 6 0 0
Pulmonary rehabilitation 60 92 4 6 1 2 0 0
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practice and that structures are put in place to ensure sys-
tematic evaluation of patients.
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